Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
NCT ID: NCT01861197
Last Updated: 2013-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
27 participants
INTERVENTIONAL
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Central Nervous System(CNS) Efficacy of Dacomitinib
NCT04675008
Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
NCT01588145
Phase 2 Study of Dacomitinib in NSCLC
NCT04027647
Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
NCT01498562
Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
NCT00452244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dovitinib monotherapy
Dovitinib
Dovitinib 500mg daily for 5 days on/ 2 day off until progression
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dovitinib
Dovitinib 500mg daily for 5 days on/ 2 day off until progression
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously treated with one or two lines of chemotherapy
* FGFR amplification (FISH \> 5 copies of genes)
* 20 years or older
* ECOG PS 0-2
Exclusion Criteria
* uncontrolled brain metastasis
* unstable angina or MI
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myung-Ju Ahn
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Myung-Ju Ahn
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-09-070-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.